Patients exposed to long acting anticoagulant rodenticides (LAARs) are typically administered large amounts of oral vitamin K1 (VK1) to counteract life-threatening anticoagulant effects. Although VK1 treatment effectively prevents mortality, additional methods are needed to reduce the long duration of VK1 treatment which can last for months at high expense. We developed a model of brodifacoum (BDF) poisoning, one of the most potent LAARs, in adult male New Zealand White (NZW) rabbits. The LD 50 for oral BDF was determined to be 192 lg/kg, similar to that calculated for adult rats. However, in contrast to rats, NZW rabbits exhibited severe internal hemorrhage including in the brain, symptoms which mimic what occurs in cases of human poisoning. Similar to warfarin, BDF and other LAARs undergo enterohepatic recirculation which contributes to their long half-lives. We therefore tested effects of cholestyramine (CSA), an FDA-approved bile sequestrant, on BDF-induced mortality. When given daily (0.67 g/kg, oral) starting the day of BDF administration, CSA reduced mortality from 67% to 11%. At the same CSA prevented the increase in clotting time, and reduced the decrease in core body temperature due to BDF. Given its excellent safety record and that it is approved for children older than 6 years, these findings suggest CSA could be considered as an adjunct to VK1 for treatment of LAAR poisoning.
manner as for warfarin overdose, namely provision of fresh frozen plasma to provide clotting factors, followed by VK1 supplementation for several days. However, other routes of exposure can result in significantly greater tissue accumulation, both unintentional (eg, accidental leakage) (Fisher et al., 2012; Masuda et al., 2015) and intentional (eg, suicide or homicide attempts) (Lipton and Klass, 1984) . BDF has also been used in attempts to inflict damage on larger groups of people, both civilians and military (Epstein et al., 2011; White, 2004 ) (reviewed in Feinstein et al., 2017) . A recent increase in patients being treated for bleeding in the Midwest region of the USA has been associated with contamination of synthetic cannabinoids with BDF (IDPH, 2018) . These concerns together with the relative ease of obtaining BDF in concentrated forms led to their designation as chemical threats (CDC) .
Although VK1 effectively restores clotting, it does not remove BDF from the body, therefore exposure to higher doses of BDF requires extended periods of VK1 treatment that can last up to a year at high cost (Gunja et al., 2011; Olmos and Lopez, 2007; Underwood et al., 2014; Weitzel et al., 1990) . In addition, BDF has VK1-independent cytotoxic actions, including induction of neuropathology (Kalinin et al., 2017; Marangoni et al., 2016b) that are not prevented by administration of VK1. For these reasons, methods that increase BDF elimination from the body would be expected to increase survival due to lethal exposure, as well as minimize the duration of VK1 treatment. One of the reasons for its long biological half-life is that, similar to warfarin, BDF undergoes enterohepatic recirculation. We therefore hypothesized that administration of cholestyramine (CSA), an FDA-approved bile sequestrant, would increase survival in BDF treated animals. Although we previously developed a rat model for BDF poisoning (Kalinin et al., 2017) , those animals did not die from massive internal bleeding but instead from small hemorrhages as well as increased systemic inflammation. We now describe development of a rabbit model for BDF poisoning which recapitulates events that occur in human cases, and show that treatment with CSA significantly increases survival in this model. Since CSA has an extremely good safety record and is approved for children as well as adults, it has potential to be used as an adjunct to VK1 to treat LAAR poisoning.
MATERIALS AND METHODS
Chemicals. BDF (CPC Scientific, Sunnyvale, California) and difenacoum (DiF) (Sigma, St Louis, Missouri) were dissolved at approximately 1.0 mg/ml in ethanol:methanol (50:50 v/v). The final concentration was determined by measuring the absorbance at 260 nm using an extinction coefficient of 0.0639 lg/ml/cm. Animals. Adult male New Zealand White (NZW) rabbits were purchased from Harlan (Envigo, Huntingdon, UK). After acclimation, animals were administered BDF at the indicated doses. For gavage, BDF stock solutions in alcohol were diluted into sterile saline to a final volume of 500 ll to provide the required dose. Animals were restrained manually and BDF administered by gavage over a period of 2-3 min. After BDF administration, the rats were housed in a chemical hazard room, to allow collection of waste and bedding contaminated with BDF. All procedures were approved by local IACUC (protocols 13-176 and 13-187).
Hematological measurements. Whole blood samples were collected in heparin BD Vacutainer Tubes (BD Biosciences, Billerica, Massachusetts) and sent to the UIC Research Laboratory services for processing of complete blood counts with differential and smear prep carried out on a Siemens Advia 120 analyzer (Siemens Corp, Washington, District of Columbia).
High performance liquid chromatography tandem mass spectroscopy (HPLC/MS-MS) analysis of BDF. Measurement of tissue BDF levels followed the protocol we recently developed (Hauck et al., 2016) . In brief, an internal standard (500-ng DiF) was added to serum samples; then samples extracted using 30% (v/v) acetone in dichloromethane. Proteins were precipitated, supernatants removed and evaporated to dryness. Samples were reconstituted in 50 ll of 25% acetone in water, then separated through an Agilent Poroshell 120 EC-C18 column using a Shimadzu (Kyoto, Japan) Nexera chromatography system. BDF was eluted using a 6-min linear gradient from 50% to 100% acetonitrile containing water at 0.55 ml/min. HPLC/MS-MS was carried out using a Shimadzu LCMS-8050 triple quadrupole mass spectrometer equipped with negative ion electrospray. BDF was measured using collision-induced dissociation with selected reaction monitoring, with argon as the collision gas. Values for BDF as presented as ng per 100 ll of serum.
Data analysis. LD 50 values were determined by Dixon analysis (Dixon and Mood, 1946) . Hematological parameters and BDF levels were compared by t tests.
RESULTS
We previously described a rat model for BDF poisoning (Kalinin et al., 2017) in which adult male Sprague Dawley rats were administered BDF either intravenously or orally. When given an LD 50 dose, 50% of the animals died within 5 days. However, upon necropsy we did not observe significant internal bleeding, instead we noted the presence of small petechial hemorrhages. To obtain a model that better reflects the bleeding that occurs in humans; we tested effects of BDF in adult male NZW rabbits. We first determined the LD 50 for acute oral administration as 192 6 29 lg/kg (mean 6 SE, Figure 1A ), similar to the value we calculated for adult rats (221 6 14 lg/kg, mean 6 Se). In contrast to rats, rabbits died by hemorrhage (Figs. 1B and 1C) including in the brain. In this model, core body temperature decreased 1 day ( Figure 2A ), and body weight decreased 1-2 days ( Figure 2B ) before the animals reached criteria for euthanization. Pharmacokinetic analysis shows that serum BDF levels were maximal 24 h after oral administration ( Figure 3A ), then showed an initial rapid decline over the next 3 days, followed by a second phase of slow elimination with BDF levels detectable at least to 10 days. Measurement of BDF tissue distribution ( Figure 3B ) shows accumulation throughout the body. Although BDF levels in most tissues (lung, kidney, spleen, and thymus) decreased between days 10 and 15, levels in liver continued to increase during that period.
We tested if CSA, a bile sequestrant which binds to substances in the gut and prevents recirculation through the enterohepatic system, would reduce BDF toxicity. Treatment with CSA (2 g/3 kg rabbit/day, for 14 days) beginning the same day that BDF was administered significantly increased survival ( Figure 4A ), reducing mortality from 66.7% to 11% ( Figure 4B ). CSA also prevented the expected increase in prothrombin time (PT) due to BDF ( Figure 5A ), as well as the decrease in core body temperature that occurred in the saline-treated group ( Figure 5B) . Measurement of hematological parameters shows that CSA also reduced the decrease in hemoglobin ( Figure 6A ), and hematocrit ( Figure 6B ) due to BDF exposure.
DISCUSSION
In this study we show that administration of BDF to adult male NZW rabbits leads to internal hemorrhage, associated with reduced core body temperature and reduced body weight. Increased internal bleeding following ingestion of LAARs are expected to occur due to the loss of active coagulation factors. In patients, the most common hemorrhagic symptoms include hematuria, gingival bleeding, epistaxis, and gastrointestinal bleeding, typically occurring 3-9 days after exposure, and the event most associated with death is intracranial bleeding (King and Tran, 2015) . Our observations of gastrointestinal bleeding as well as cerebral hemorrhage help validate the use of NZW rabbits as a model for studies to identify countermeasure for BDF (and other LAAR) poisoning.
In contrast to rabbits, studies carried out in adult male Sprague Dawley rats (Kalinin et al., 2017) revealed upon necropsy that animals that died from BDF did not show massive internal bleeding, but only small petechial lesions. A similar species specific response was described to occur in large cats accidentally exposed to LAARs. Examination of 27 bobcats suffering from mange infection revealed that all 27 had been exposed to an LAAR ; however, clotting times for all animals were found to be within normal limits, and variances in hematocrit were not correlated to LAAR levels. In contrast, examination of mountain lions from the same geographic area who were also exposed to LAARs revealed that 4 adult lions died directly from anticoagulant effects (Riley et al., 2007) . In a separate study, analysis of mRNA expression levels in blood samples from 52 bobcats, of which 26 had detectable exposure to LAARs but without signs of coagulation dysfunction, revealed significant changes in over 1700 mRNA, including many related to immune function (Fraser et al., 2018) . These observations are consistent with findings that topical application of warfarin can elicit direct inflammatory responses in skin explants and epithelial cells (Mirkov et al., 2017; Popov Aleksandrov et al., 2015) , and that in normal healthy adult mice, treatment with warfarin significantly increased neuroglial activation throughout the brain (Marangoni et al., 2016a) . Moreover, X-ray scattering studies show that LAARs such as BDF, but not warfarin, interact with and perturb lipid membrane structures that can result in cellular dysfunction (Marangoni et al., 2016b) , including cytotoxicity in diverse cell types (Kalinin et al., 2017; Marangoni et al., 2016b) . Together, the data suggest that LAAR exposure which may be insufficient to induce sufficient bleeding and acute death can be causative for increases in inflammatory responses as well as decreases in protective immune responses such as infection and wound healing.
We also observed a decrease in core body temperature, which preceded by 1-2 days the progression of clinical signs to the state requiring euthanasia (inappetance, decreased activity, pallor). The mechanism(s) responsible for this phenomenon were not elucidated in the present study. However, in both rats and rabbits, hypothermia occurs following administration of bacterial endotoxin lipopolysachharide (LPS) or the cytokine interleukin-1 (Schramek and Brezina, 1976; Weinberg et al., 1988) ; and in rabbits infusion of the nitric oxide mimetic sodium Figure 3 . BDF tissue distribution. Adult male NZW rabbits were administered BDF (0.20 mg/kg, once by gavage), then samples taken at indicated times for HPLC/MS-MS quantitation of BDF levels. A, Serum levels. The data is the mean 6 SE from n ¼ 15 animals at the beginning of the study, which was reduced to n ¼ 9 at 192 and 240 h. B, Tissue levels. Data are mean 6 SE from n ¼ 3 (day 4), n ¼ 4 (day 8), and n ¼ 2 (day 15). nitroprusside produced hypothermia and reduced fever (Gagalo et al., 1995) . In humans, hypothermia can be a key sign of severe sepsis; it is associated with higher mortality and may be an early indicator of immune suppression (Drewry et al., 2015) . These reductions in body temperature may be due to release of antipyretic substances from peripheral macrophages, including tumor necrosis factor alpha (TNFa) (Derijk and Berkenbosch, 1994) . The observed reductions in core body temperature could therefore reflect initial stages of a systemic inflammatory condition. Alternatively, it has been shown that BDF reduces mitochondrial function (Marangoni et al., 2016b) ; hence reduced body temperature could be a consequence of reduced energy dissipation during oxidative phosphorylation, which could be exacerbated by lower hematocrit, reduced tissue perfusion and progressive anemia which all contribute to inadequate tissue oxygenation. Consistent with this, it has been reported that certain xenobiotic toxins and some pesticides decrease the metabolic rate of rabbits leading to hypothermia, postulated as a compensatory responses to minimize lethality which in many cases increases with body temperature (Gordon et al., 1988) .
We also observed that BDF reduced serum levels of hemoglobin and hematocrit. A likely explanation is induction of microor macrohemorrhages allowing for blood loss throughout the body, in the absence of sufficiently rapid repopulation of red blood cells. This is consistent with our previous findings in rats (Ware et al., 2015) in which treatment with BDF led to a rapid (within 1 day), but transient decrease in hematocrit which was followed by a delayed (after 10 days) hematuria. This suggests that in rabbits the reduction in hematocrit may also reflect an early phase of anticoagulation.
Till now, the accepted treatment for LAAR poisoning follows the same strategy as for warfarin, namely plasma products followed by supplementation with VK1. However, in contrast to a few days, treatment for LAAR exposure with VK1 may be required for months to over a year. In a meta-analysis of 41 cases of LAAR poisoning, 29 were known to be due to BDF. Analysis of those cases shows that the average dose of VK1 administered was close to 100 mg/day, given for over 120 days (King and Tran, 2015) . Since current FDA-approved VK1 costs up to $60 for a single 5-mg tablet, the above dosing regimens can be prohibitively expensive. Figure 5 . CSA prevents anticoagulation and maintains core body temperature. Adult male NZW rabbits were administered BDF (0.2 mg/kg, once by gavage). A, PT was measured at 0, 4, 8, and 10 days. Data is mean 6 se. For saline, group sizes were 10, 9, 8, and then 5 at day 10; for CSA, group sizes were 15, 10, 9, and then 8 at day 10. B, Core body temperature measured at the indicated times. The data is the mean temperature 6 SE. The initial group size in the saline cohort was n ¼ 6; during the study 4 rabbits died (on days 7.4, 9.4, 10.5, and 11.6). The initial group size in the CSA cohort was n ¼ 10. During the study, 1 rabbit died on day 10.4. When an animal died, its last measured body temperature was recorded for all subsequent days to calculate the group mean. Figure 6 . CSA reduces loss of red blood cells and hemoglobin. Adult male NZW rabbits were administered BDF (0.2 mg/kg, once by gavage). Blood samples were taken on the indicated days and used to measure the hematological parameters. (A) Hemoglobin; (B) Hematocrit. Data are mean 6 SE. For saline group sizes were n ¼ 3, 6, 5, then 4 on day 10; for CSA group sizes were 7, 10, 9, and 9 on day 10.
More importantly, VK1 does not reduce LAAR levels, therefore interruption in treatment can result in reappearance of symptoms after months of successful treatment (Gunja et al., 2011; Hollinger and Pastoor, 1993; Underwood et al., 2014) . In addition, any possible delayed consequences of LAARs remaining in the body, including neuropathological (Kalinin et al., 2017) or renal (Ware et al., 2013 (Ware et al., , 2015 would not be averted by VK1.
A likely limiting factor in removal of LAARs is that, similar to warfarin (McAleer et al., 1992; Wong et al., 1978) , strongly hydrophobic LAARs like BDF undergo enterohepatic recirculation (Watt et al., 2005) . The enterohepatic recirculation system functions to maintain bile salts in the body, needed for digestive processes. In the 1960s, it was discovered that high molecular weight resins when ingested bind to bile salts, prevent their recirculation, and increase their elimination. Since bile salts are generated from cholesterol, these resins lead to rapid and dramatic reductions in total cholesterol levels. Amongst the resins developed, CSA was found efficacious at binding bile and reducing cholesterol (Huff et al., 1963; Van Itallie et al., 1961) . CSA is FDA-approved for ages 6 and older, and has an excellent safety profile since it is not absorbed. Although originally used as a cholesterol lowering agent, it is currently approved for treatment of pruritus, an itchiness of the skin due to accumulation of bile salts. In addition, CSA is also currently FDArecommended for cases of overdoses of several drugs including meloxicam (Mobic) (Lehr et al., 2009 ) and mycophenolate (CellCept) (van Gelder et al., 2001; Wu et al., 2008) . CSA is also effective in accelerating clearance of other FDA-approved drugs in cases of overdoses or toxicities, including troglitazone (Loi et al., 1999) , thyroxin (de Luis et al., 2002) , leflunomide (MerinoSanjuan et al., 2004; Savage et al., 2006) , digoxin (Henderson and Solomon, 1988) , and amiodarone (Goddard and Whorwell, 1989) . These considerations prompted us to test if CSA would increase survival following exposure to BDF. Following administration of 0.20 mg/kg, 67% of the animals died or reached criteria for euthanasia within 12 days. In contrast, daily treatment with CSA reduced mortality to 11% (1 of 9 animals died). At the same time the increase in PT which occurred between days 4 and 8 postBDF did not occur when CSA was given.
In summary, these findings provide strong evidence that treatment with CSA can significantly improve survival. This suggests that CSA was able to reduce BDF levels sufficiently to prevent suppression of VKORC1 activity and thereby maintain adequate VK1 levels needed for activation of coagulation factors. However, it remains to be confirmed that CSA increases BDF elimination, and if so what are the kinetics of that actions. Although we attempted to measure fecal BDF levels to confirm increased elimination, our established extraction procedure was not able to dissociate BDF from CSA, thereby preventing quantitative analysis. Similarly, a full pharmacokinetic analysis of tissue BDF levels in CSA versus saline-treated animals will be required to establish the kinetics and magnitude of CSA effects on serum as well as liver and brain accumulation. It also remains to be determined if survival is sustained after cessation of CSA treatment, or if repeat treatments will be necessary to eliminate remaining BDF that can accumulate in, and gradually released from tissue storage sites such as adipose tissue and muscle. 
